Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 7/20 | 0.37 |
| ▸ | PPARD | Q03181 | 5/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 8/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 2/20 | 0.35 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1932221 | 0.93 | L3MBTL1 (0.39) | L3MBTL1PPARAPPARDSMN1; SMN2ALDH1A1 | |
| SCHEMBL6900965 | 0.92 | L3MBTL1 (0.40) | L3MBTL1PPARAPPARDSMN1; SMN2ALDH1A1 | |
| SCHEMBL1931744 | 0.92 | L3MBTL1 (0.40) | L3MBTL1PPARAPPARDSMN1; SMN2ALDH1A1 | |
| SCHEMBL1931835 | 0.92 | L3MBTL1 (0.40) | L3MBTL1PPARAPPARDSMN1; SMN2ALDH1A1 | |
| SCHEMBL1930555 | 0.92 | L3MBTL1 (0.40) | L3MBTL1PPARAPPARDSMN1; SMN2ALDH1A1 | |
| SCHEMBL15546034 | 0.84 | PPARA (0.40) | L3MBTL1PPARAPPARDSMN1; SMN2ALDH1A1 | |
| SCHEMBL1932886 | 0.83 | L3MBTL1 (0.38) | L3MBTL1PPARAPPARDALDH1A1MEN1 | |
| SCHEMBL1930559 | 0.83 | S1PR1 (0.44) | L3MBTL1S1PR1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL1930762 | 0.83 | S1PR1 (0.40) | L3MBTL1S1PR1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL1931299 | 0.82 | EPHX2 (0.37) | L3MBTL1S1PR1SMN1; SMN2ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110130445-A1 | SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130445-A1 | SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF | FABP3, PC, PAH | L3MBTL1 2594/4885PPARA 5/4885PPARD 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.